Clinical Value of C-reactive Protein and Erythrocyte Sedimentation Rate in Advanced Bladder Cancer

Abstract

Background: The identification of biomarkers would improve the management of advanced urinary bladder carcinoma. Aim: The current study assessed the potential prognostic role of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in advanced stage bladder cancer. Methods: Forty-six patients with advanced urinary bladder carcinoma were included in the study. After consent, CRP and ESR were measured before treatment, after 2 cycles of chemotherapy and at the end of treatment. The relation between CRP and ESR serum measurements and patients' characteristics and treatment response were assessed. Results: Both CRP and ESR were elevated in all included patients with mean values ± standard deviation: 35.43 ± 12.65 and 57.17 ± 18.15, respectively. The baseline CRP level was higher in patients with metastatic disease. ESR was significantly elevated in association with squamous cell carcinoma pathology and hydronephrosis and in patients who died within one year of diagnosis (p = 0.003, 0.001 and 0.03; respectively). Patients who experienced disease progression after 2 cycles of platinum-based chemotherapy had higher levels of CRP and ESR. Serial measurements during the course of treatment revealed that both CRP and ESR levels declined significantly during treatment mainly among responding patients (p = 0.001). Conclusion: CRP and ESR might be useful noninvasive biomarkers in advanced urinary bladder carcinoma.

Como a eritrossedimentação tem contribuído nas patologias oncológicas?: uma revisão integrativa

“…21 Brazilian Journal of Health Review, Curitiba, v. Com isso, creem que essas medições podem ser uteis no acompanhamento neste grupo de pacientes, porém com a ressalva de ser feita uma confirmação em um estudo com maior número de pacientes. 26 Balatoni e colaboradores realizaram um estudo para avaliar a viabilidade do ipilimumabe fora dos ensaios clínicos, identificando preditores de sobrevivência como benefício do tratamento. Encontraram valores significativamente maiores em pacientes que tiveram doença progressiva na 24ª semana do que nos pacientes que tinham a doença controlada.…”

“…Chegaram a conclusão que o VHS é o marcador basal da eficácia do nivolumabe, a PCR é útil para prever a eficácia antes e durante o tratamento. 26 Exames de sangue comum, entre eles o VHS, foram analisados a fim de identificar se a vigilância regular dos pacientes com linfoma agressivo que alcançam a remissão completa após quimioterapia combinada de primeira linha, seria detectada. O resultado foi negativo, não sendo possível detectar recidiva de linfoma agressivo em pacientes assintomáticos com os tratamentos atuais.…”